Progress in the treatment of neonatal hypoxic-ischemic encephalopathy with umbilical cord blood mononuclear cells

Zhou, Jiayu; Gao, Ting; Tang, Wan; Qian, Tianyang; Wang, Ziming; Xu, Pu; Wang, Laishuan

doi:10.1016/j.braindev.2023.09.001

Cited by 1 publication

(1 citation statement)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Regulation of immune and anti-inflammatory effects and reduce inflammatory cell infiltration into the wound. HUCB-MNCs secrete growth factors, such as hepatocyte growth factor, insulin-like growth factor, VEGF, bFGF and anti-inflammatory cytokines, such as IL-10 66 , which have antiapoptotic and antinecroptotic effects on ischaemic and injured cells. McDonald et al demonstrated that UCB and special types of UCB cells, such as EPCs and monocytes, can regulate peripheral and central immune responses 67 .…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease

Cai,

Li,

Gao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Ischaemic bowel disease (ICBD) is a group of intestinal ischaemia syndromes caused by various aetiologies of reduced intestinal blood flow or vascular occlusion. ICBD can present as abdominal pain, bloody stool, and diarrhoea. This disease often occurs in middle-aged and elderly individuals with cardiovascular and cerebrovascular diseases. The incidence of ischaemic bowel disease has been increasing for decades, and it is difficult to diagnose, resulting in rapid disease progression and a high mortality rate. Therefore, fully understanding this disease, improving the diagnosis rate of this disease, and finding appropriate treatment methods are urgently needed to improve the condition and prognosis of patients. Umbilical cord blood stem cells are accessible, have weak immunogenicity, and have various biological functions, such as angiogenesis, inflammation and immune regulation. Many studies have confirmed that cord blood stem cells can relieve ischaemia, and these cells have attracted tremendous amounts of attention in regenerative medicine in recent years. In this paper, we discuss the clinical characteristics of ICBD, analyse the characteristics of human umbilical cord blood mononuclear cells (HUCB-MNCs), and use its to treat ischaemic bowel disease. Additionally, we compare the clinical manifestations and related indicators before and after treatment to evaluate the efficacy and safety of these methods.

show abstract

Section: Discussionmentioning

confidence: 99%